Skip to content

D46.A

Billable

Refractory cytopenia with multilineage dysplasia

Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)

Is D46.A an HCC code?

Yes. D46.A maps to Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers under the CMS-HCC V28 risk adjustment model (and Severe Hematological Disorders under V24).

HCC Category Mapping

V28HCC 19Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers
1.798
V24HCC 46Severe Hematological Disorders
1.372
ESRDHCC 46Severe Hematological Disorders
0.223
RxHCCHCC 19Leukemias and Other Hematologic Cancers
1.949

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for D46.A

For D46.Ato count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D46.A during that encounter — not just copy-forwarded from a problem list.

What This Code Means

D46.A is the ICD-10-CM diagnosis code for refractory cytopenia with multilineage dysplasia. A bone marrow disorder where multiple types of blood cells are abnormal and cannot be produced normally, with excess immature cells. D46.A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (d37-d48).

Under the CMS-HCC V28 risk adjustment model, D46.A maps to Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers (HCC 19) with a community, non-dual, aged base RAF weight of 1.798. Under the older CMS-HCC V24 model, D46.A maps to Severe Hematological Disorders (HCC 46) with a community, non-dual, aged base RAF weight of 1.372. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

This code requires documentation of dysplasia in at least two cell lines. Because D46.A maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D46.A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • This code requires documentation of dysplasia in at least two cell lines
  • Confirm the absence of ring sideroblasts and specific blast percentages to ensure correct subtype assignment

Clinical Significance

Refractory cytopenia with multilineage dysplasia is a myelodysplastic syndrome subtype affecting at least two blood cell lineages (red cells, white cells, and/or platelets), leading to multiple cytopenias. This condition indicates a more widespread bone marrow failure than single-lineage subtypes and carries intermediate prognostic risk with potential for leukemic transformation.

Documentation Requirements

  • Documentation must include bone marrow biopsy confirming dysplastic changes in at least two cell lineages (erythroid, granulocytic, and/or megakaryocytic).
  • Blast percentage must be below 5%, and ring sideroblasts should be absent or below 15%.
  • Document all affected blood counts, cytogenetic results, and International Prognostic Scoring System risk score.

Commonly Confused Codes

  • D46.B (refractory cytopenia with multilineage dysplasia and ring sideroblasts) includes ring sideroblasts in addition to multilineage dysplasia.
  • D46.0 (refractory anemia without ring sideroblasts) affects only the erythroid lineage.
  • D46.20-D46.22 (excess blasts) indicate higher blast percentages.
  • D61.9 (aplastic anemia, unspecified) is a different bone marrow failure mechanism.

Code Hierarchy

Open D46.A in the Interactive Encoder

See full code details, AI coding tips, HCC mappings, and related codes in our interactive encoder. Start your 14-day Pro trial — no credit card required.